Merck KGaA

Merck KGaA, branded globally as Merck, is a German multinational science and technology company headquartered in Darmstadt, Germany. Founded in 1668, it is the world's oldest operating chemical and pharmaceutical company. The company operates as a public entity listed on the Frankfurt Stock Exchange (FWB: MRK), with the founding Merck family retaining a majority ownership stake of approximately 70% through E. Merck KG. As of late 2025, Merck KGaA employed over 62,000 people across 65 countries and reported annual revenues in the range of €21-24 billion. It is important to distinguish Merck KGaA from the unrelated American pharmaceutical company, Merck & Co. (known as MSD outside the U.S. and Canada); in the U.S. and Canada, Merck KGaA's businesses operate under different brand names.

Merck KGaA's operations are divided into three main business sectors: Healthcare, Life Science, and Electronics. The Healthcare sector focuses on discovering, developing, manufacturing, and marketing prescription drugs and biopharmaceuticals, with key therapeutic areas including oncology, neurology & immunology, fertility, and cardiovascular, metabolic, and endocrinological disorders. In the Life Science sector, the company provides products and services to academic labs, biotech, and pharmaceutical companies, including high-grade chemicals, consumables, and Contract Development and Manufacturing Organization (CDMO) services; this business operates as MilliporeSigma in the U.S. and Canada. The Electronics sector is a major supplier of materials and solutions for the semiconductor and display industries, offering products like advanced dielectric materials, photoresists, and liquid crystals, operating as EMD Electronics in North America.

In terms of patent litigation, Merck KGaA exhibits the posture of an operating company that actively enforces its intellectual property. The company has one tracked case as a plaintiff and zero as a defendant in our database. This indicates a focus on asserting its own patents, likely related to its core pharmaceutical, life science, or electronics innovations, rather than frequently being targeted by patent assertion entities.

The single tracked case is Merck KGaA v. Hopewell Pharma Ventures, Inc., filed in October 2022 in the Delaware District Court. Hopewell Pharma Ventures, Inc. is described as a pharmaceutical company that develops and commercializes generic and specialty pharmaceutical products, often navigating intellectual property challenges and patent validity. This context suggests the litigation is a direct dispute between two operating companies over pharmaceutical product-related patents.